Details

Autor(en) / Beteiligte

• Stanberry, Lawrence R
• Spruance, Spotswood L
• Cunningham, Anthony L
• Bernstein, David I
• Mindel, Adrian
• Sacks, Stephen
• Tyring, Stephen
• Aoki, Fred Y
• Slaoui, Moncef
• Denis, Martine
• Vandepapeliere, Pierre
• Dubin, Gary

Titel

Glycoprotein-D–Adjuvant Vaccine to Prevent Genital Herpes

Ist Teil von

• The New England journal of medicine, 2002-11, Vol.347 (21), p.1652-1661

Ort / Verlag

Boston, MA: Massachusetts Medical Society

Erscheinungsjahr

2002

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Two double-blind, controlled trials assessed the efficacy of a glycoprotein-D–subunit vaccine to prevent genital herpes disease. The vaccine elicited humoral and cellular responses, but efficacy was found only in women who were seronegative for both herpes simplex virus type 1 (HSV-1) and herpes simplex virus type 2 (HSV-2) (efficacy in the two studies was 73 and 74 percent). The vaccine was not efficacious in women who were seronegative for HSV-2 if they were seropositive for HSV-1, nor was it efficacious in men. Genital infection caused by herpes simplex virus type 1 (HSV-1) or herpes simplex virus type 2 (HSV-2) may be asymptomatic, mild, and unrecognized as herpes or severe with painful skin lesions and complications including urinary retention and meningitis, as well as substantial psychological illness. 1 – 8 Genital HSV infection occurs worldwide and appears to be epidemic in some populations despite the availability of condoms and chemoprophylaxis. 9 – 11 Evidence suggests that only the widespread use of an effective vaccine might control this epidemic. 12 We describe the results of two multicenter, double-blind, randomized, controlled studies of an HSV-2 glycoprotein-D–subunit vaccine formulated with a . . .